Medicus Pharma LTD F-1 registration statements

Medicus Pharma Ltd. files for a U.S. IPO to raise capital for clinical trials of its SkinJect microneedle array for basal cell carcinoma treatment, offering units at an assumed price of $4.55.

Medicus Pharma Ltd. files an amendment to its F-1 registration statement for a proposed offering of units, each consisting of a common share and a warrant, aiming for a Nasdaq listing.

Medicus Pharma is seeking to raise capital and list on the Nasdaq through an offering of 500,000 units, each comprising a common share and a warrant.

Medicus Pharma Ltd. is seeking to raise capital and list on the Nasdaq through an offering of 1,200,000 units, each comprising a common share and a warrant.

Medicus Pharma Ltd. is seeking to raise capital and list on the Nasdaq through an offering of 1.2 million units, each comprising a common share and a warrant.

Medicus Pharma Ltd. files an amendment to its F-1 registration statement for a proposed offering of 1,200,000 units, aiming for a Nasdaq listing.

Medicus Pharma Ltd. files for a U.S. IPO to raise capital for clinical trials of its SkinJectTM treatment for basal cell carcinoma.

Medicus Pharma Ltd. is undertaking a unit offering, each unit comprising a common share and a warrant, to fund the clinical development of SkinJect, a novel treatment for basal cell carcinoma.

Medicus Pharma Ltd. has filed a warrant agency agreement and an amended registration statement related to its upcoming public offering of units consisting of common shares and warrants.

Medicus Pharma Ltd. intends to raise up to $10 million through convertible notes and prepares for a U.S. IPO, aiming to advance its skin cancer treatment.